AMRI, a global contract research, development and manufacturing organization working with the life sciences industry, is expanding leading container closure integrity testing (CCIT) services into the European Union.
The company will build out custom laboratory space for CCIT in its Valladolid, Spain, analytical facility; additional analytical services, including reference standards and ICH stability testing, will follow later in 2018.
AMRI analytical services head Mark Stier said: "Within the last several years, the life sciences industry has pivoted toward quantitative methods for integrity testing of sterile package systems, with regulatory agencies increasingly demanding these more modern technologies,"
"As our client base for this critical service continues to grow in Europe, this expansion is a logical step in our mission to provide comprehensive testing solutions to customers across the globe."
The expansion of these services to the EU complements the existing local expertise in chromatographic analytical method development and the future build-out of reference standard and ICH stability facilities at the site.
Overall, the expansion positions AMRI to provide its complete suite of services to European customers, and deliver a more comprehensive solution for drug discovery, development and manufacturing.
Additionally, the company will be exhibiting at the PDA Parenteral Packaging 2018 conference from February 27-28 in Rome, Italy. AMRI, a global contract research and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life.
With locations in North America, Europe and Asia, AMRI's team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical Services, API Manufacturing and Drug Product.